Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods

Area of Science:

• Pharmacology and Clinical Laboratory Science
• Cardiovascular Medicine and Thrombosis

Background:

• Clopidogrel, a P2Y12 receptor antagonist, is crucial for preventing thrombotic events.
• Suboptimal clopidogrel response is linked to adverse cardiovascular outcomes.
• Genetic variations, particularly in CYP2C19, impact clopidogrel metabolism and efficacy.

Purpose of the Study:

• To review current laboratory testing methods for monitoring clopidogrel therapy.
• To highlight the clinical relevance of assessing clopidogrel response.
• To inform healthcare providers about genetic testing for CYP2C19 variants.

Main Methods:

• Review of published literature on clopidogrel monitoring.
• Summary of available platelet function assays.
• Discussion of CYP2C19 genotyping techniques.

Main Results:

• Laboratory tests can detect clopidogrel-induced platelet inhibition.
• Genetic polymorphisms influence clopidogrel bioavailability and effectiveness.
• FDA black-box warning emphasizes the impact of genetic factors.

Conclusions:

• Laboratory monitoring of clopidogrel therapy is gaining importance.
• Platelet function tests and genetic testing offer valuable insights.
• Personalized antiplatelet therapy may improve patient outcomes.